natgillin/translations-raw huggingface dataset:
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, ipconazole, prothioconazole, tebuconazole, propiconazole, cyproconazole, and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Figure 3 is directed to the base 100 and the various components that are associated with the base's recessed well 300 . 
Slika 3 se odnosi na postolje 100 i različite dijelove koji su povezani s dubokim spremnikom 300 postolja.
The target-binding moiety toxin conjugate of claim 1, wherein the amatoxin is connected to the target-binding moiety or, if present, to the linker L3 via an oxygen atom bound to the δ C-atom of amatoxin amino acid 3. 
Konjugat za ciljno vezanje djela toksina prema zahtjevu 1, naznačen time što je amatoksin povezan sa sponom L2 preko kisikovog atoma vezanog za 6' C-atomom amatoksinske aminokiseline 4.
Short chain fibres, e.g. oligofructose, are fermented first, in the beginning of the colon. 
Vlakna kratkih lanaca, npr. oligofruktoza, fermentiraju se prva, u početnom dijelu debelog crijeva.
In certain embodiments, the angiotensin II converting enzyme (ACE) inhibitors is selected from captopril, enalapril, lisinopril, benazepril, quinapril, fosinopril, and ramipril. 
Spoj ili pripravak prema zahtjevu 11, naznačen time da se inhibitor ACE bira iz skupine koju čine kaptopril, enalapril, lizinopril, benazepril, kinapril, fosinopril, te ramipril.
A recombinant antibody molecule, or an a4-binding fragment thereof, comprising a variable heavy chain and a variable light chain, wherein: 
PATENTNI ZAHTJEVI Rekombinantna molekula protutijela ili njezin fragment koji veže a4, naznačena time, da obuhvaća varijabilni jaki lanac 1 varijabilni slabi lanac, pri čemu:
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof; provided that the group —N(R2)—CO—R1 cannot be an unsubstituted 2-oxopyrrolidin-1-yl group or an unsubstituted 2-oxoimidazolin-1-yl group if simultaneously the group R3—X-Het- is a group of the formula 
HR P20120167 TI u bilo kojem od njegovih stereoizomernih oblika ili smjesi stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol; uz uvjet da skupina -N(R")-CO-R' ne može biti nesupstituirana 2-oksopirolidin-1-ilna skupina ili nesupstituirana 2- oksoimidazolin-1-ilna skupina ako je istodobno skupina R*-X-Het- skupina formule
The composition for the use according to claim 1, wherein the anti-RSV immune response inducing composition administered to said infant is a prime or a boost. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na navedenom dojenčetu početni ili dodatni.
The method of claim 21, wherein said the primer set is further used together with SEQ ID NO:14 and SEQ ID NO:15. 
Postupak prema zahtjevu 20, pri čemu se spomenuta mješavina začetnica također koristi skupa sa SEQ ID NO je: 14 i SEQ ID NO: 15.
each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C1-6alkyl, amino, polyhaloC1-6alkyl, aryl, arylC1-6alkyl or C1-6alkyloxy; or each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from methylenedioxy or ethylenedioxy; 
svaki piridinil, indolil, kinolinil, imidazolil, furanil, tienil, oksadiazolil, tetrazolil, benzofuranil ili tetrahidrofuranil može biti proizvoljno supstituiran sa jednim, dva ili tri supstituenta svakim nezavisno odabranim od halo, hidroksi, C1-6alkila, amino, polihaloC1-6alkila, arila, arilC1-6alkila ili C1-6alkiloksi; ili svaki piridinil, indolil, kinolinil, imidazolil, furanil, tienil, benzofuranil, ili tetrahidrofuranil može biti proizvoljno supstituiran sa bivalentnim radikalom odabranim od metilendioksi ili etilendioksi;
The inventors have detected that the processes according to the invention allow the manufacture of a large variety of various veneers having a first-class quality in an economical manner. 
Izumitelji su pronašli, da postupak koji je u skladu s ovim izumom omogućava proizvodnju mnogo varijanti različitih furnira koji imaju prvoklasnu kvalitetu u komercijalnom pogledu.
Said inshoe 227 is provided with suitable holes 231 (or, in an equivalent manner, can be breathable) at the region of the sole 211 assigned to permeation; it is evident that the inshoe 227, in an extreme case, can also be perforated with a single “macroperforation”. 
Navedena unutarnja cipela 227 izrađena je s odgovarajućim perforacijama 231 (ili jednako tako može biti izrađena od prozračnog materijala) u području potplata 211, koje je namijenjeno propuštanju pare; očito je da unutarnja cipela 227, u ekstremnom slučaju, također može biti perforirana s jednom "makroperforacijom".
A compound of formula Ia or a pharmaceutically acceptable salt thereof, for therapeutic use in improving the quality of life of a patient treated for metastatic or unresectable melanoma with vemurafenib or a pharmaceutically acceptable salt thereof. 
Spoj, naznačen time, da ima formulu Ia: HO la, te služi za terapeutsku primjenu u svrhu poboljšanja kvalitete života pacijenta koji se liječi od raka prostate pomoću abiraterona.
The pharmaceutical composition of claim 8, wherein the composition is administered in combination with radiation or a chemotherapeutic agent. 
Farmaceutski sastav prema patentnom zahtjevu 26, gdje farmaceutski sastav nadalje sadrži kemoterapeutsko sredstvo.
phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one or two halogen; 
fenilC1−6alkil, pri čemu je navedeni fenilC1−6alkil nesupstituiran ili supstituiran s jednim ili dva halogena;
a first structural truss panel fastened to the at least one structural column; and a second structural truss panel fastened to the at least one structural column and arranged in substantially the same plane as the first structural truss panel, wherein the second structural truss panel is vertically spaced from the first structural truss panel such that loads placed on the first and second structural truss panels are transferred to the at least one structural column, wherein the at least one substantially vertical structural column is configured to connect to a second substantially vertical structural column using a top connector of the at least one substantially vertical structural column and a bottom connector of the second substantially vertical structural column and wherein the top connector is a bolt and the bottom connector is a hole configured to receive the bolt. 
Postupak za izgradnju zgrade, naznačen time da sadrži: pričvršćivanje prve konstrukcijske rešetkaste ploče (20), navedena prva konstrukcijska rešetkasta ploča je konstrukcijska ploča kako je definirano u zahtjevu 1, na prvi konstrukcijski stup; pričvršćivanje drugog konstrukcijskog stupa okomito izravno na prvi konstrukcijski stup; i, pričvršćivanje druge konstrukcijske rešetkaste ploče (20) na drugi konstrukcijski stup tako da je druga konstrukcijska rešetkasta ploča okomito iznad prve konstrukcijske rešetkaste ploče, tako da postoji zazor između prve i druge konstrukcijske rešetkaste ploče (20), te tako da se okomito trenutno i stalno opterećenje i bočno opterećenje prenose bočno na prvi i drugi konstrukcijski stup i zatim okomito između prvog i drugog stupa umjesto na okomitu konstrukcijsku rešetkastu ploču na konstrukcijsku rešetkastu ploču.
Perforated lid (10) according to any of the previous claims, characterised in that the lower surface of said upper plate (13) and the lower surface of said at least one intermediate plate (12) have a concavity facing downwards. 
Perforirani poklopac (10) prema bilo kojem od prethodnih zahtjeva, naznačen time što konkavna strana donje površine gornje ploče (13) i donje površine barem jedne srednje ploče (12) gleda prema dolje.
The alkyl chain is the portion of the molecule that binds to HMG-CoA reductase. 
Alkilni lanac dio je molekule koji se veže za HMG-CoA reduktazu.
A recombinant expression vector comprising a nucleic acid molecule according to claim 8. 
Rekombinantni ekspresijski vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu 8.
A light source as claimed in claim 1, wherein the plasma crucible is contoured to reflect light in a particular direction. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1 ili 2, naznačen time, da je plazmena retorta homogena.
Figure 1 is a simplified schematic view of a recycling device according to the present invention; 
Slika 1 = prikazuje shematski pojednostavljeni pogled na uređaj za recikliranje koji je u skladu s predmetnim izumom;
Wind system (1) according to claim 3, characterised in that said wheels (16, 17) are interfaced with said module (5) through springs coupled in parallel with dampeners. 
Vjetreni sustav (1) prema zahtjevu 6, naznačen time da je spomenuta rastegnuta fleksibilna konstrukcija (12) opremljena jednom okomitom rešetkastom konstrukcijom (13).
It is indicated for the treatment of spasticity and painful reflex muscle spasms associated with various musculoskeletal diseases, for example lumbago, spastic states after spinal or brain trauma, stroke, perinatal head injuries, or sclerosis multiplex, amyotrophic lateral sclerosis, etc. 
On se propisuje za liječenje grčeva i bolnih refleksnih mišićnih grčeva povezanih s raznim mišićno-koštanim bolestima, kao što su, na primjer lumbago, spastična stanja nakon spinalne ili moždane traume, udara kapi, perinatalnih ozljeda glave, ili multiple skleroze, amiotrofne lateralne skleroze, itd.
Use according to Claim 11, which is characterized in that, said pyrazolone compound or the salt thereof is used to control the harmful plant in a desirable crop. 
Uporaba prema zahtjevu 12, naznačena time, da se navedeni pirazolonski spoj ili njegova sol upotrebljavaju za kontrolu štetne biljke u poželjnoj kulturi.
A vaccine component comprising the immunogenic polypeptide fragment of embodiment 37. 
Komponenta cjepiva koja sadrži imunogenski polipeptid prema zahtjevu 9.
The compound or salt of claim 19, wherein said cancer is a solid tumor, prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, hematological cancer, lymphoma, leukemia, multiple myeloma, skin cancer, cutaneous T-cell lymphoma or cutaneous B-cell lymphoma. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak izabran od raka prostate, raka bubrega, raka jetre, raka želuca, raka štitne žlijezde, glioblastoma, Kaposijevog sarkoma, Castlemanove bolesti, melanoma, T-staničnog kožnog limfoma (CTCL), B-staničnog kožnog limfoma, Sezary sindroma, "mycosis fungoides" (kronični T-stanični limfom), akutne limfoblastične leukemije i kolorektalnog raka.
a compound selected from the group consisting of sulfonylureas, including their respective isomers a s well as their respective environmentally compatible salts or esters or amides or other derivatives; 
Sinergistička herbicidna smjesa koja sadrži A) imazamoks, njegove odgovarajuće izomere, kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom; i
A compound, which is or a pharmaceutically acceptable salt or stereoisomer thereof. 
Spoj s formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time da: X je C=O ili CH2;
The building section of claim 2, further comprising first and second stud sections and first and second attachment plates, wherein the first stud section is attached to the first structural column, wherein the second stud section is attached to the second structural column, wherein the first attachment plate is coupled between the first structural truss panel and the first stud section, and wherein the second attachment plate is coupled between the second structural truss panel and the second stud section. 
Postupak prema zahtjevu 4, naznačen time da nadalje sadrži: pričvršćivanje prvog rešetkastog nosača poda i/ili stropa na integrirani rešetkasti dio prve konstrukcijske rešetkaste ploče tako da prva rešetka poda i/ili stropa nosi element koji sadrži strop prvog prostora definiranog barem djelomično s prvom strukturnom rešetkastom pločom (20) i pod od drugog prostora definiranog barem djelomično s drugom strukturnom rešetkastom pločom (20); te
The use of claim 5, wherein the high-altitude cerebral edema is vasogenic edema. 
Primjena prema patentnom zahtjevu 5, naznačena time, što je visinski edem mozga vazogeni edem.
ii) preparing the fraction of fine particles a), by co-mixing the excipient particles and the additive particles in a high-energy apparatus for a period of less than 20 minutes; iii) mixing said fraction of fine particles a), said fraction of coarse particles b), and all the micronized active ingredients. 
priprava frakcije finih čestica a) miješanjem u visokoenergijskoj aparaturi u periodu manjem od 20 minuta, ii) miješanjem rečene frakcije finih čestica a), s frakcijom grubih čestica b), i svih mikroniziranih aktivnih tvari.
The method of claim 1, wherein the parent virus is a mutant of a natural isolate. 
matični virus je mutant prirodnog izolata.
applying a first solution that optionally comprises poly (ethylene glycol) and glycine to a cation exchange chromatographic material thereby equilibrating the material, 
- nanošenje prve otopine koja po potrebi obuhvaća poli(etilenglikol) 1 sorbitol za kationsku izmjenu kromatografskog materijala, te time uravnotežavanje materijala,
A candle holder arrangement as claimed in any one of claims 1 to 7 wherein the candle holder (10) comprises a lip (18) extending transversely away from the candle holder (10). 
Aranžman sa svijećnjakom sukladno bilo kojem od Zahtjeval do 7 pri čemu svijećnjak (10) sadrži usnicu (18) koja se transverzalno pruža od svijećnjaka (10).
separating the second organic phase of step (d) containing trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol; and 
separacije druge organske faze iz koraka (d) koja sadrži trans-(-)-A9-tetrahidrokanabinol i trans-(+)-A9-tetrahidrokanabinol; i
The method of claim 5, wherein the cell comprises a single vector which comprises a nucleic acid encoding SEQ ID NO:4 and a nucleic acid encoding SEQ ID NO:3. 
Postupak prema zahtjevu 9, naznačen time da stanica sadrži jedan vektor koji sadrži nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 3 i nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4.
It is noted that as the key 22 moves linearly through keyway 42, the key combination element 26 moves radially as it pivots about pivot axis 36 . 
Napominje se da kako se ključ 22 pomiče linearno duž prolaz 42 ključa, element kombinacije ključa 26 se pomiče radijalno dok se okreće oko osi vrtnje 36.
encoding at least one isolated IL-23p19 antibody according to claim 1 or claim 2; or 
(a) kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;
The AvPAL variant of item 26, wherein said pegylation is achieved by reacting the AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of AvPAL variant. The AvPAL variant of item 26, wherein at least 28 percent of lysine residues at positions 2, 10, 32, 145, 195, 301, 413, 493, and 522 of the AvPAL variant are pegylated. 
AVvPAL varijanta u skladu s patentnim zahtjevom 17, naznačena time, da je barem 28 & lizinskih ostataka na položajima 2, 10, 32, 145, 195, 301, 413, 493 te 522 AvPAL varijante pegilirano, pri čemu je barem 51 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 413, 493 te 522 AvPAL varijante ili pri čemu je najmanje 75 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 493 1 522 AvPAL varijante.
The polymer conjugate of any of claims 1 to 4, wherein the polymers moiety is covalently linked to the HMGB1 Box-A polypeptide, HMGB1 Box-A polypeptide variant or a biologically active fragment thereof. 
Polimerni konjugat iz bilo kojeg od zahtjeva 1 do 4, naznačen time, što je polimerna komponenta kovalentno vezana za HMGB1 Box-A polipeptid, HMGB1 Box-A polipeptidnu varijantu ili njihov biološki aktivni fragment.
A process according to any one of claims 1 to 5 in which the compound of formula (I) contains a moiety NRcRd and wherein Rc and Rd together with the adjoining nitrogen form a 5- or 6- membered heterocyclic ring, optionally substituted as by 0, 1, 2, 3, 4 or 5 substituents selected from straight chain or branched C1, C2, C3 or C4 alkyl, halogen and C1, C2, C3 or C4 alkoxy, wherein alkyl and the alkyl part of alkoxy are unsubstituted or substituted by halogen. 
Spoj prema bilo kojem od zahtjeva 14 do 16, naznačen time, da sadrži polovicu NRcRd gdje Rc i Rd zajedno s priključenim dušikom tvore 5- ili 6-člani heterociklički prsten, po izboru supstituiran s 0, 1, 2, 3, 4 ili 5 supstituenata odabranih od ravnolančanih ili razgranatih C1, C2, C3 ili C4 alkila, halogena i C1, C2, C3 ili C4 alkoksi, pri čemu su alkil i alkilni dio od alkoksi nesupstituirani ili supstituirani halogenom.
The modified LCAT protein of any one of claims 1-4 for use in a therapeutic method of increasing HDL in a subject. 
Modificirani LCAT protein prema patentnom zahtjevu 15 za uporabu u postupku za liječenje ili prevenciju kardiovaskularne bolesti.
reaction of a compound of Formula (2) with a compound of Formula (3): 
R3 R1 (2) (3) b) reakciju spoja formule (4) sa spojem formule (5):
5- or 6-membered heteroaryl selected from oxadiazolyl, pyrazinyl, pyrimidinyl, and pyridinyl; wherein said heteroaryl independently is optionally mono-substituted with (C1-3)alkyl; or —NR11R12, wherein 
5-člani ili 6-člani heteroaril odabran od oksadiazolila, pirazinila, pirimidinila, i piridinila; gdje je navedeni heteroaril nezavisno opcionalno mono-supstituiran s (C1-3)alkilom; ili
a 5' wing segment consisting of three linked nucleosides; and a 3' wing segment consisting of three linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. 
5 segment,krila" koji se sastoji od tri vezana nukleozida; i 3' segment,,krila" koji se sastoji od tri vezana nukleozida; pri čemu se segment razmaka nalazi između 5* segmenta,,krila" i 3* segmenta, krila"; pri čemu svaki nukleozid iz svakog segmenta,krila" obuhvaća cEt šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza; 1 pri čemu svaki citozin je 5-metilcitozin.
The pharmaceutical composition for use as claimed in claim 1, wherein the method of therapy is a method of treatment or prevention of a cancer characterized by expression of the tumor-associated antigen according to claim 1, in which the cancer is an esophageal tumor, an ovarian tumor, a head-neck tumor, a kidney tumor, a liver tumor, a lung tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, a stomach cancer, a pancreatic tumor, a renal cell carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutski pripravak za primjenu sukladno zahtjevu 1, pri čemu je postupak terapije postupak liječenja ili prevencije karcinoma, naznačena ckspresijom antigena povezanog tumora sukladno zahtjevu 1, pri čemu je karcinom poželjno tumor jednjaka, tumor jajnika, tumor glave-vrata, tumor bubrega, tumor jetre, tumor pluća, tumor dojke, tumor prostate, tumor debelog crijeva, tumor želuca, karcinom želuca, tumor pankreasa, karcinom bubrežnih stanica, karcinom debelog crijeva ili karcinom dojke.
The method of claim 2, wherein the predetermined amount is 40%. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je specificirani postotak 40%.
contacting the contaminant material with the solvent composition, wherein the contaminant material is asphalt, heavy asphaltenic materials, hydrogen-deficient carbonaceous materials, coke, tar, heavy oil deposits, hydrocarbon sludge, lube oil or any combination thereof; and allowing the solvent composition to react with the contaminant material such that at least a portion of the contaminant material is no longer attached to the industrial equipment. 
(B) izazivanja kontakta između kontaminiranog materijala 1 formulacije otapala, naznačeno time, što je kontaminirani materijal asfalt, teški asfaltenski materijali, ugljični materijali deficitarni vodikom, koks, katran, naslage teških ulja, ugljikovodični talog, ulje za podmazivanje ili bilo koja njihova kombinacija; 1 (C) omogućavanja formulaciji otapala da reagira s kontaminiranim materijalom tako da najmanje dio kontaminiranog materijala više ne bude pričvršćen na industrijsku opremu.
ET-743 is currently formulated as a sterile lyophilized product containing 250 µg active substance per dosage unit, 250 mg mannitol as a bulking agent and 0.05 M phosphate buffer at pH 4 in order to solubilize ET-743. 
ET-743 je trenutno oblikovan kao sterilni liofilizirani proizvod koji sadrži 250 ug aktivne tvari po jedinici doze, 250 mg manitola kao punila i 0.05 Ivi fosfatnog pufera na pH 4 u cilju otapanja ET-743.
The product contained small amounts of starting material. 
Produkt sadrži male količine početnog materijala.
In this recess 38 the beams 35 and 36 are visible and the auxiliary column 31 can be mounted to the beams 35, 36 by means of self tapping screws or the like which are inserted through a hole in the auxiliary column 31. 
U ovom udubljenju 38 vidljive su grede 35 136 i pomoćni stup 31 može se pričvrstiti na grede 35 i 36 uz pomoć samouvojnih vijaka ili sličnih elemenata koji se ulažu kroz provrt u pomoćnom stupu 31.
The number and types of aberrations found, the percentage of structurally damaged cells (percent aberrant cells) in the total population of cells examined, and the mean aberrations per cell were calculated and reported for each treatment group. 
Broj i tipovi nađenih aberacija, postotak strukturno oštećenih stanica (postotak aberantnih stanica) u ukupnoj populaciji ispitivanih stanica, i srednji broj aberacija po stanici su izračunavani i prikazani za svaku grupu tretmana.
A freeze-dried aripiprazole formulation obtained by a process comprising the steps of spray-freezing an aripiprazole suspension containing 
Zamrzavanjem osušena formulacija aripiprazola naznačena time da se dobiva postupkom koji sadrži korake smrzavanja raspršivanjem suspenzije aripiprazola koja sadrži
The method according to any of the claims 1 to 5, wherein the component c) is selected among N-methylpyrrolidone, dimethyl sulfoxide, 2-propanol, tetrahydrofuran, propylene carbonate, gamma-butyrolactone, cyclohexanone, tetrahydrothiophene-1,1-dioxide, N-cyclohexyl-2-pyrrolidone and tetramethylurea. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 1 do 5, naznačena time da je komponenta označena slovom c) odabrana između N-metilpirolidona, dimetil sulfoksida, 2-propanola, tetrahidrofurana, propilen karbonata, gama- butirolaktona, cikloheksanona, tetrahidrotiofen-1, 1-dioksid, N-cikloheksi-2-pirolidon i tetrametiluree.
The process of claim 1 wherein step d) is effected at 20 to 40°C, preferably at room temperature. 
Postupak iz patentnog zahtjeva 1 naznačeno time da je korak d) proveden pri 20 do 40°C, preferirano pri sobnoj temperaturi.
A non-naturally occurring and/or purified and/or engineered cell, especially a T-cell, presenting a TCR as claimed in claim 1 . 
Stanica koja ne postoji u prirodi i/ili je pročišćena i/ili konstruirana, koja prezentira TCR sukladno bilo kojem od patentnih zahtjeva 1-7.